Ketamine therapy is legal in the United States, but the rules depend on what form of ketamine you’re talking about, where you receive it, and what condition it’s being used for. The short answer: a licensed provider can legally prescribe ketamine for psychiatric conditions like depression, but this falls into a regulatory gray area because the FDA has only approved ketamine as an anesthetic, not as a mental health treatment.
Federal Legal Status
Ketamine became a Schedule III controlled substance under the Controlled Substances Act in 1999. That classification means it has accepted medical uses but also carries potential for abuse, moderate physical dependence, and high psychological dependence. Being Schedule III (rather than the more restrictive Schedule I or II) is actually what makes ketamine therapy possible. Any practitioner licensed to prescribe Schedule III substances, including psychiatrists, anesthesiologists, emergency medicine doctors, and primary care physicians, can legally prescribe it.
The DEA controls the manufacturing, distribution, and dispensing of ketamine, but its ability to regulate how the drug is actually used inside a medical setting is significantly limited. That’s why ketamine infusion clinics have been able to operate across the country without a specific federal framework governing them.
Off-Label Use: The Legal Gray Area
Here’s the part that confuses most people. Ketamine is FDA-approved only as an anesthetic and sedation agent. It is not FDA-approved for the treatment of any psychiatric disorder. That includes depression, anxiety, PTSD, and chronic pain. Yet thousands of clinics offer it for exactly these purposes.
This is possible because of off-label prescribing, a longstanding and fully legal practice in medicine. Once the FDA approves a drug for any indication, doctors can prescribe it for other conditions at their professional discretion. Off-label prescribing is common across all specialties and is not unique to ketamine. However, as the Journal of the American Academy of Psychiatry and the Law has noted, this creates a situation where “the legal status of use of the drug for this purpose is not entirely clear.” Most states have little to no specific regulation of psychiatric ketamine use, leaving clinical decisions largely up to individual providers.
The American Psychiatric Association has responded to this unregulated landscape with a consensus statement emphasizing careful patient selection, monitoring, and integration of ketamine into a broader treatment plan that includes psychotherapy and other medications.
Esketamine: The FDA-Approved Option
There is one ketamine-related product that does have full FDA approval for psychiatric use. Spravato, a nasal spray containing esketamine (a chemical mirror image of the ketamine molecule), is approved for two specific conditions: treatment-resistant depression in adults, and depressive symptoms in adults with major depressive disorder who have active suicidal thoughts or behavior.
Spravato comes with strict requirements that generic ketamine does not. It’s available only through a restricted program called a REMS (Risk Evaluation and Mitigation Strategy), which exists because of concerns about sedation, dissociation, breathing problems, and misuse. In practice, this means:
- You cannot take it at home. Spravato can only be dispensed and administered in certified healthcare settings.
- You self-administer under observation. You spray it yourself, but a healthcare provider watches and monitors you for at least two hours afterward.
- The clinic and pharmacy must be certified. Both the treatment facility and the dispensing pharmacy must be enrolled in the REMS program.
The typical treatment schedule starts with twice-weekly sessions for the first month, then drops to once weekly for the next month, and eventually shifts to every one or two weeks for ongoing maintenance.
What About At-Home Ketamine?
Several telehealth companies have offered compounded ketamine products, including lozenges, tablets, and nasal sprays, for patients to use at home. This is the most legally and medically uncertain corner of ketamine therapy.
Compounded ketamine products are not FDA-approved, meaning the agency has never evaluated their safety, effectiveness, or quality. The FDA issued a specific warning about these products, highlighting that at-home use without medical monitoring puts patients at risk. Known dangers include abuse, psychiatric side effects, blood pressure spikes, slowed breathing, and bladder damage. In one 2023 case reported to the FDA, a patient taking compounded oral ketamine at home for PTSD experienced dangerous breathing suppression, with blood levels reaching roughly twice what would be used for surgical anesthesia.
The FDA has not established safe dosing for ketamine for any psychiatric condition. Compounded products exist in a legal space where a licensed prescriber can order them and a compounding pharmacy can fill them, but neither the product nor the use has regulatory approval. Some states have begun scrutinizing these arrangements more closely.
State-by-State Differences
While federal law sets the baseline, states add their own layer of regulation, particularly around who can administer ketamine and under what supervision. These rules vary significantly.
Kentucky’s Board of Nursing, for example, spells out detailed scope-of-practice rules. Licensed practical nurses cannot administer ketamine at all. Registered nurses can administer subanesthetic doses but only under the direct supervision of a qualified healthcare provider and only if they have the appropriate training. Advanced practice nurses, such as certified nurse anesthetists and psychiatric mental health nurse practitioners, have broader authority to both prescribe and independently administer subanesthetic ketamine for psychiatric disorders and chronic pain.
Other states may have looser or stricter rules. The ownership of ketamine clinics is influenced by each state’s Corporate Practice of Medicine doctrine, which governs whether non-physicians (such as business investors) can own a medical practice. In some states, a ketamine clinic must be physician-owned. In others, the business structure can be more flexible as long as a licensed physician oversees clinical care.
Insurance Coverage
Spravato is the only ketamine-based treatment with a clear path to insurance reimbursement. Medicare and many private insurers cover it when administered at a REMS-certified facility for the approved diagnoses of treatment-resistant depression or major depression with suicidal ideation. The treatment has specific billing codes, and coverage generally follows the FDA-labeled dosing schedule.
Generic ketamine infusions for depression or other psychiatric conditions are a different story. Because these uses are off-label and the treatments are administered in private clinics, most insurance plans do not cover them. Patients typically pay out of pocket, with a single infusion session often running between $400 and $800. A standard initial course of six infusions over two to three weeks can cost several thousand dollars before any maintenance sessions.
Legal Status in Other Countries
Ketamine’s legal classification varies internationally. In the United Kingdom, ketamine is controlled as a Class B substance, with penalties for illegal supply or production reaching up to 14 years in prison. The UK government is currently reviewing whether ketamine should be reclassified as a Class A drug, the most restrictive category, due to rising recreational misuse. Clinical use for mental health in the UK exists but is more limited than in the United States.
Canada and Australia both allow medical use of ketamine under controlled conditions, though the regulatory frameworks and availability of ketamine clinics differ. In general, the United States has one of the most permissive environments for off-label ketamine therapy, largely because of the broad discretion given to prescribers and limited state-level regulation of infusion clinics.